VHL and nonpapillary renal cell carcinoma: Patients with low TMB exhibited improved clinical outcomes, while distinct mutational profiles between high-TMB and low-TMB groups (e.g., VHL mutations in high TMB vs. DNAH9 in low TMB) emphasized the genomic heterogeneity of ccRCC and the need for tailored therapies.